PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model

Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2016, Pages 123-132

  Haraya, Kenta ^a   Tachibana, Tatsuhiko ^a   Iwayanagi, Yuki ^b   Maeda, Atsuhiko ^b   Ozeki, Kazuhisa ^b   Nezu, Junichi ^a   Ishigai, Masaki ^b   Igawa, Tomoyuki ^b  

^a Chugai Pharmabody Research Pte Ltd   (Singapore)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

FcRn; Monoclonal antibody; pH dependent antigen binding; PK PD; TMDD

Indexed keywords

MONOCLONAL ANTIBODY; ANTIGEN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; ASSOCIATION RATE CONSTANT; CONTROLLED STUDY; DRUG CLEARANCE; HUMAN; MALE; MOUSE; NONHUMAN; PH; RECYCLING; VOLUME OF DISTRIBUTION; ANIMAL; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; CHEMISTRY; IMMUNOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; BINDING SITES, ANTIBODY; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; PROTEIN BINDING;

EID: 84961230926     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2015.12.007     Document Type: Article

References (41)

1. J.G. Elvin, R.G. Couston, and C.F. van der Walle Therapeutic antibodies: market considerations, disease targets and bioprocessing Int J Pharm 440 2013 83 98
2. J.M. Reichert Marketed therapeutic antibodies compendium MAbs 4 2012 413 415
3. A.P. West Jr., and P.J. Bjorkman Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor Biochemistry 39 2000 9698 9708
4. W.L. Martin, A.P. West Jr., L. Gan, and P.J. Bjorkman Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding Mol Cell 7 2001 867 877
5. F. Mimoto, T. Igawa, T. Kuramochi, H. Katada, S. Kadono, T. Kamikawa, and et al. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant MAbs 5 2013 229 236
6. S.R. Frankel, and P.A. Baeuerle Targeting T cells to tumor cells using bispecific antibodies Curr Opin Chem Biol 17 2013 385 392
7. T.S. Raju, and W.R. Strohl Potential therapeutic roles for antibody mixtures Expert Opin Biol Ther 13 2013 1347 1352
8. S.Y. Ko, A. Pegu, R.S. Rudicell, Z.Y. Yang, M.G. Joyce, X. Chen, and et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection Nature 514 2014 642 645
9. J. Corne, R. Djukanovic, L. Thomas, J. Warner, L. Botta, B. Grandordy, and et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics J Clin Invest 99 1997 879 887
10. D.L. Mortensen, S. Prabhu, E.G. Stefanich, S. Kadkhodayan-Fischer, T.R. Gelzleichter, D. Baker, and et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies MAbs 4 2012 724 731
11. P. Hodsman, C. Ashman, A. Cahn, E. De Boever, N. Locantore, A. Serone, and et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics Br J Clin Pharmacol 75 2013 118 128
12. J.J. Xiao, W. Krzyzanski, Y.M. Wang, H. Li, M.J. Rose, M. Ma, and et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys AAPS J 12 2010 646 657
13. G.C. Jayson, C. Mulatero, M. Ranson, J. Zweit, A. Jackson, L. Broughton, and et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer Eur J Cancer 41 2005 555 563
14. R.J. Kelly, A. Hill, L.M. Arnold, G.L. Brooksbank, S.J. Richards, M. Cullen, and et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival Blood 117 2011 6786 6792
15. R.C. Strunk, and G.R. Bloomberg Omalizumab for asthma N Engl J Med 354 2006 2689 2695
16. T. Igawa, S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, and et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat Biotechnol 28 2010 1203 1207
17. T. Igawa, A. Maeda, K. Haraya, T. Tachibana, Y. Iwayanagi, F. Mimoto, and et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo PLoS One 8 2013 e63236
18. T. Igawa, F. Mimoto, and K. Hattori pH-dependent antigen-binding antibodies as a novel therapeutic modality Biochim Biophys Acta 1844 2014 1943 1950
19. B. Wu, A. Joshi, S. Ren, and C. Ng The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab J Pharm Sci 95 2006 1258 1268
20. C.M. Ng, E. Stefanich, B.S. Anand, P.J. Fielder, and L. Vaickus Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers Pharm Res 23 2006 95 103
21. Y. Vugmeyster, C. Rohde, M. Perreault, R.E. Gimeno, and P. Singh Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design MAbs 5 2013 373 383
22. A.M. Betts, T.H. Clark, J. Yang, J.L. Treadway, M. Li, M.A. Giovanelli, and et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis J Pharmacol Exp Ther 333 2010 2 13
23. S.C. Devanaboyina, S.M. Lynch, R.J. Ober, S. Ram, D. Kim, A. Puig-Canto, and et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics MAbs 5 2013 851 859
24. J. Chaparro-Riggers, H. Liang, R.M. DeVay, L. Bai, J.E. Sutton, W. Chen, and et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J Biol Chem 287 2012 11090 11097
25. M.W. Traxlmayr, E. Lobner, C. Hasenhindl, G. Stadlmayr, C. Oostenbrink, F. Ruker, and et al. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution Biotechnol J 9 2014 1013 1022
26. C. Stein, L. Kling, G. Proetzel, D.C. Roopenian, M.H. de Angelis, E. Wolf, and et al. Clinical chemistry of human FcRn transgenic mice Mamm Genome 23 2012 259 269
27. L.P. Boulet, K.R. Chapman, J. Cote, S. Kalra, R. Bhagat, V.A. Swystun, and et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response Am J Respir Crit Care Med 155 1997 1835 1840
28. M.A. Alyanakian, E. Bernatowska, J.M. Scherrmann, P. Aucouturier, and J.L. Poplavsky Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes Vox Sang 84 2003 188 192
29. A.W. Tolcher, M. Mita, N.J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, and et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 J Clin Oncol 25 2007 1390 1395
30. A.D. Ricart, A.W. Tolcher, G. Liu, K. Holen, G. Schwartz, M. Albertini, and et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study Clin Cancer Res 14 2008 7924 7929
31. K. Haraya, T. Tachibana, M. Nanami, and M. Ishigai Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody Xenobiotica 44 2014 1127 1134
32. S.H. Tam, S.G. McCarthy, K. Brosnan, K.M. Goldberg, and B.J. Scallon Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities MAbs 5 2013 397 405
33. A.T. Jones, and H.J. Ziltener Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies Blood 82 1993 1133 1141
34. T. Moritz, N. Niederle, J. Baumann, D. May, E. Kurschel, R. Osieka, and et al. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease Cancer Immunol Immunother 29 1989 144 150
35. J. Kosola, J.P. Vaara, M. Ahotupa, H. Kyrolainen, M. Santtila, N. Oksala, and et al. Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men Metabolism 62 2013 992 999
36. T.A. Waldmann, A. Iio, M. Ogawa, O.R. McIntyre, and W. Strober The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma J Immunol 117 1976 1139 1144
37. F.J. Malveaux, M.C. Conroy, N.F. Adkinson Jr., and L.M. Lichtenstein IgE receptors on human basophils. Relationship to serum IgE concentration J Clin Invest 62 1978 176 181
38. W. Wang, X. Wang, R. Doddareddy, D. Fink, T. McIntosh, H.M. Davis, and et al. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys AAPS J 16 2014 129 139
39. Z. Xu, Q. Wang, Y. Zhuang, B. Frederick, H. Yan, E. Bouman-Thio, and et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J Clin Pharmacol 50 2010 276 284
40. Y. Zhu, Q. Wang, B. Frederick, E. Bouman-Thio, J.C. Marini, M. Keen, and et al. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies Clin Drug Investig 33 2013 291 301
41. P.S. Daugherty, G. Chen, M.J. Olsen, B.L. Iverson, and G. Georgiou Antibody affinity maturation using bacterial surface display Protein Eng 11 1998 825 832